Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why Eleven Bio, SouFun, Glaukos, Match Group, and Triumph Group Are Surging Today

U.S. stocks continue to tumble on Wednesday, driven by weak economic data out of the U.S, disappointing corporate financial results, and declining metal prices. However, as usual, a few stocks are moving in the opposite direction. Among the day’s most relevant gainers are Eleven Biotherapeutics Inc (NASDAQ:EBIO), SouFun Holdings Ltd (NYSE:SFUN), Glaukos Corp (NYSE:GKOS), Match Group Inc (NASDAQ:MTCH) and Triumph Group Inc (NYSE:TGI), all of which are posting significant surges in the afternoon. Let’s take a look into the events behind these notable spikes, and see how the hedge funds in our database have been trading these companies lately.

Our research has shown that the best strategy is to follow hedge funds into their small-cap picks. This approach can allow monthly returns of nearly 95 basis points above the market, as we determined through extensive backtests covering the period between 1999 and 2012 (see the details here).

Eleven Biotherapeutics Spikes on Renewed Hope for Isunakinra

Let’s begin with Eleven Biotherapeutics Inc (NASDAQ:EBIO), which is up by roughly 34.8% on more than 6-times its regular trading volume today. Shares have now gained more than 316% over the past month, regaining some of the ground lost in May of 2015 and January of 2016; however, the stock is still down by almost 90% in relation to where it was a year ago. But, why the tumble and sudden recuperation? Well, the company’s isunakinra had originally failed late-stage trials for dry eye disease and allergic conjunctivitis. Nonetheless, more recently, post hoc analysis showed that the drug candidate would likely be effective among a group of patients with particular genetic patterns of IL-1 (interleukin-1).

Among the funds that we track, very few were in a position to benefit from a spike in Eleven Biotherapeutics Inc (NASDAQ:EBIO)’s stock. Only three firms in our database were long the stock at the end of 2015.

Follow Sesen Bio Inc. (NASDAQ:SESN)
Trade (NASDAQ:SESN) Now!

SouFun’s Stock Moving To Shanghai

Next up is SouFun Holdings Ltd (NYSE:SFUN), which is up by 9.3% on Wednesday afternoon, on news that the company plans to change its stock listing from the U.S to mainland China in an attempt to boost its valuation. As part of the migration process, SouFun will swap assets and shares with Chongqing Wanli New Energy Co.; however, the deal still needs to be approved by regulators.

Unlike Eleven Biotherapeutics, SouFun Holdings Ltd (NYSE:SFUN) is quite popular among hedge funds. As of the end of 2015, the company counted 18 supporters in our database, who held roughly 8.4% of its total shares. A noteworthy position was that of Kerr Neilson’s Platinum Asset Management, which held 16.67 million shares of the company on December 31.

Follow Soufun Holdings Ltd (NYSE:SFUN)
Trade (NYSE:SFUN) Now!

We cover three more surging stocks on the next page.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.